Island Pharma Announces ISLA-101 Clinical Trial Progress
In Island’s Phase 2a trial, participants receive ISLA-101 before exposure to a weakened dengue virus developed by the U.S. Army. The study evaluates whether ISLA-101 can reduce viremia and symptoms compared to a placebo. Following the completion of dosing on October 3, 2024, Island has collected samples to assess changes in viral load, pharmacokinetics, and other blood analyses.
Island Pharma Announces ISLA-101 Clinical Trial Progress